XtalPi has entered a strategic partnership valued at more than $400m with an international biopharmaceutical company to develop oral small-molecule therapeutics targeting a G protein-coupled receptor (GPCR).
Stellar is a manufacturer of KLH, an immune-stimulating protein widely used as a carrier molecule in the development of immunotherapies. Spain-based Araclon is majority-owned by global healthcare firm
Selinexor works by inhibiting the nuclear export protein XPO1, leading to the accumulation of tumor suppressor proteins in the cell nucleus, which subsequently reinitiates and amplifies their tumor
The partnership provides clinical and pathology laboratories that have adopted Cartagenia’s Bench for Oncology software platform for their genetic sequencing analysis and reporting workflow with the option to
To support and advance this molecule, Encycle Therapeutics is collaboratively partnering with the Institute for Research in Immunology and Cancer — Commercialization of Research (IRICoR), the Université de
The portfolio includes leading brands built by strong levels of professional recommendations which have demonstrated excellent growth potential. The brands Lipo-Flavonoid®, Certain Dri®, Cystex®, Albolene, Absorbine Jr.®, and
If successful, the company could then move forward with medical research investigating whether or not the product is efficacious in areas like cancer, post-traumatic stress disorder, concussions, epilepsy,
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.
